Completed PHASE2 INTERVENTIONAL 2-arm NCT00497159

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease (DIMOND)

A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease

Sponsor: Huntington Study Group

Conditions Huntington's Disease

Interventions Dimebon Placebo

Updated 8 times since 2017 Last updated: May 16, 2015 Started: Jul 31, 2007 Primary completion: Jun 30, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00497159, this PHASE2 trial focuses on Huntington's Disease and remains completed. Sponsored by Huntington Study Group, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Huntington Study Group
Medivation, Inc.

Data source: Medivation, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States